| Dr Kaveh Karimnejad, MD | |
|
1025 Marsh St, Mankato, MN 56001-4752 | |
| (507) 625-4031 | |
| Not Available |
| Full Name | Dr Kaveh Karimnejad |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 12 Years |
| Location | 1025 Marsh St, Mankato, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144583584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 64538 (Minnesota) | Primary |
| 207Y00000X | Otolaryngology | 306319 (Louisiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Region Healthcare Corporation | Fergus falls, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Region Healthcare Corporation | 3971565334 | 109 |
News Archive
UNAIDS Executive Director Peter Piot on Thursday encouraged the Chinese government to provide compensation and medical care to thousands of people who contracted HIV through the government-supported blood transfusions in the late 1990s and early 2000s, AFP/AsiaOne News reports.
A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
› Verified 1 days ago
| Entity Name | Lake Region Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093713372 PECOS PAC ID: 3971565334 Enrollment ID: O20060109000246 |
News Archive
UNAIDS Executive Director Peter Piot on Thursday encouraged the Chinese government to provide compensation and medical care to thousands of people who contracted HIV through the government-supported blood transfusions in the late 1990s and early 2000s, AFP/AsiaOne News reports.
A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
› Verified 1 days ago
| Entity Name | Andros Ent & Sleep Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578807491 PECOS PAC ID: 0244478188 Enrollment ID: O20130604000638 |
News Archive
UNAIDS Executive Director Peter Piot on Thursday encouraged the Chinese government to provide compensation and medical care to thousands of people who contracted HIV through the government-supported blood transfusions in the late 1990s and early 2000s, AFP/AsiaOne News reports.
A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740256668 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003933 |
News Archive
UNAIDS Executive Director Peter Piot on Thursday encouraged the Chinese government to provide compensation and medical care to thousands of people who contracted HIV through the government-supported blood transfusions in the late 1990s and early 2000s, AFP/AsiaOne News reports.
A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kaveh Karimnejad, MD 1025 Marsh St, Mankato, MN 56001-4752 Ph: (507) 256-4031 | Dr Kaveh Karimnejad, MD 1025 Marsh St, Mankato, MN 56001-4752 Ph: (507) 625-4031 |
News Archive
UNAIDS Executive Director Peter Piot on Thursday encouraged the Chinese government to provide compensation and medical care to thousands of people who contracted HIV through the government-supported blood transfusions in the late 1990s and early 2000s, AFP/AsiaOne News reports.
A new study on cocaine, the notorious white powder illegally snorted, injected or smoked by nearly 2 million Americans, details how it may permanently damage proteins in the body. That information, gleaned from laboratory tests, could be used to potentially detect the drug in biofluids for weeks or months - instead of days - after use, say scientists. The findings, which appear in the ACS journal Chemical Research in Toxicology, could also help explain cocaine's long-term health effects.
Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.
BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.
Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a settlement agreement with Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc., a Canadian federal corporation; Biocad Médical Inc., a Quebec provincial corporation; Nobel Biocare USA, LLC, a Delaware limited liability company; and Nobel Biocare Procera, LLC, a Delaware limited liability company; (collectively "Nobel Entities") pursuant to which it settled civil actions in the United States, Canada, Italy and Germany involving the Nobel Entities and Sinblab.
› Verified 1 days ago
Grace Nimat Khouri, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1230 E. Main Street, Mankato Clinic, Ltd, Mankato, MN 56002 Phone: 507-625-1811 Fax: 952-843-4301 | |
Fareeda Taher Nazer Hussain, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-594-4700 | |
Mark G Cardamone-rayner, Otolaryngology Medicare: Medicare Enrolled Practice Location: 1015 Marsh St, Mankato, MN 56001 Phone: 507-389-4700 | |
Susan E Pearson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1421 Premier Dr, Mankato, MN 56001 Phone: 507-624-1811 | |
Willard James Michalski, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 112 Beech Street, Mankato, MN 56001 Phone: 507-625-1589 |